Enpicom Secures €1.2M Series A Funding to Advance ImmunoGenomiX (IGX) Sequencing Data Analysis Platform

VCBeat (WeChat Official Account:(VCBeat) learned from foreign media reports，Recently, a biomedical software development companyEnpicomAnnouncement of CompletionAWheel12010,000 euros in financing. This round of financing was led byBOM Brabant VenturesLead investor,Nextgen VenturesandArches CapitalCo-investment, with the raised funds to be used forImmunoGenomix（IGX) platform development and market promotion.

Enpicom, founded in 2015 and headquartered in North Brabant, the Netherlands, is an innovative biomedical software development company. The company specializes in providing software technology support to immunotherapy developers, accelerating the discovery and development of novel immunotherapies.

In mid-2017, Enpicom developed the ImmunoGenomix (IGX) platform, which isNo. 1 in the MarketindividualComprehensive Sequencing Data Analysis Platform for Managing, Storing, Analyzing, and Interpreting Clonal Sequencing Data of T-Cell and B-Cell Receptor RepertoiresCurrently, the company is inImmunoGenomix（IGX) the final stage of preparations for the platform’s global promotion. According to information on the official website,4Month11Day-to13On [date], the company will launch at the 6th Cancer Immunotherapy Conference held in ViennaImmunoGenomix（IGX) full version of the platform.

Dr. Nicola Bonzanni, Sales Director at Enpicom, stated, “The ability to directly measure and closely monitor cell states is critically important when researching immune-related diseases or developing related therapeutics. Bulk sequencing is an efficient approach that enables the rapid analysis of hundreds of thousands to millions of T-cell or B-cell receptors. We are delighted to have completed our Series A financing; the new capital will accelerate the final development of our ImmunoGenomix (IGX) platform and support the launch of corresponding market promotion initiatives.”

Sjoerd van Gorp, Investment Manager at BOM Brabant Ventures, stated, “The Enpicom team has innovatively integrated data science with medicine, and the IGX platform they have developed will have a significant societal impact. This platform provides effective tools for innovative life sciences companies and healthcare providers to measure patients’ immune system status, thereby enabling the delivery of effective treatments.”

BOM Brabant Ventures was established in 1983 and is headquartered in North Brabant, the Netherlands. The organization focuses on supporting startups in North Brabant to scale up, particularly those in advanced technology sectors such as high-tech systems and materials, bio-agriculture, life sciences, and medical technology.

Nextgen Ventures is an investment fund based in Gelderland, the Netherlands. The fund focuses on investing in knowledge-intensive startups, aiming to drive the development of the healthcare industry.

Arches Capital, established in 2012, is a venture capital fund based in Illinois. The firm focuses on investing in deep-tech software companies, including those in FinTech, RegTech, MedTech, cybersecurity, and enterprise software.

(Compiled by Yang Shiying)